Strategies to Preclude Hepatitis C Virus Entry

Thierry Pierre Robert Burnouf; Ching Hsuan Liu; Liang-Tzung Lin

doi:10.5772/65470

Strategies to Preclude Hepatitis C Virus Entry

Thierry Pierre Robert Burnouf, Ching Hsuan Liu, Liang-Tzung Lin

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Without a preventive vaccine, hepatitis C virus (HCV) remains an important pathogen worldwide with millions of carriers at risk of end-stage liver diseases. Despite the introduction of novel direct-acting antivirals (DAAs), resistance problems, challenges with the difficult-to-treat populations and high costs limit the widespread application of these drugs. Antivirals with alternative mechanism(s) of action, such as by restricting viral entry or cell-to-cell spread, could help expand the scope of antiviral strategies for the management of hepatitis C. Transfusion-associated HCV infection remains another issue in endemic and resource-limited areas around the world. This chapter describes some of the latest developments in antiviral strategies to preclude HCV entry, such as through monoclonal antibodies and small molecules, as well as measures to enhance the safety of therapeutic plasma products in blood transfusion.

Original language	English
Title of host publication	Advances in Treatment of Hepatitis C and B
Publisher	InTech
ISBN (Electronic)	978-953-51-2994-3
ISBN (Print)	978-953-51-2993-6
DOIs	https://doi.org/10.5772/65470
Publication status	Published - Mar 8 2017

Fingerprint

Keywords

hepatitis C virus
viral entry
antivirals
entry inhibitors
monoclonal antibodies
small molecules
therapeutic plasma products

Cite this

Burnouf, T. P. R., Liu, C. H., & Lin, L-T. (2017). Strategies to Preclude Hepatitis C Virus Entry. In Advances in Treatment of Hepatitis C and B InTech. https://doi.org/10.5772/65470

@inbook{990ca64c818e476f932c84ff240a4750,

title = "Strategies to Preclude Hepatitis C Virus Entry",

abstract = "Without a preventive vaccine, hepatitis C virus (HCV) remains an important pathogen worldwide with millions of carriers at risk of end-stage liver diseases. Despite the introduction of novel direct-acting antivirals (DAAs), resistance problems, challenges with the difficult-to-treat populations and high costs limit the widespread application of these drugs. Antivirals with alternative mechanism(s) of action, such as by restricting viral entry or cell-to-cell spread, could help expand the scope of antiviral strategies for the management of hepatitis C. Transfusion-associated HCV infection remains another issue in endemic and resource-limited areas around the world. This chapter describes some of the latest developments in antiviral strategies to preclude HCV entry, such as through monoclonal antibodies and small molecules, as well as measures to enhance the safety of therapeutic plasma products in blood transfusion.",

keywords = "hepatitis C virus, viral entry, antivirals, entry inhibitors, monoclonal antibodies, small molecules, therapeutic plasma products",

author = "Burnouf, {Thierry Pierre Robert} and Liu, {Ching Hsuan} and Liang-Tzung Lin",

year = "2017",

month = mar

day = "8",

doi = "10.5772/65470",

language = "English",

isbn = "978-953-51-2993-6",

booktitle = "Advances in Treatment of Hepatitis C and B",

publisher = "InTech",

address = "Croatia",

}

TY - CHAP

T1 - Strategies to Preclude Hepatitis C Virus Entry

AU - Burnouf, Thierry Pierre Robert

AU - Liu, Ching Hsuan

AU - Lin, Liang-Tzung

PY - 2017/3/8

Y1 - 2017/3/8

N2 - Without a preventive vaccine, hepatitis C virus (HCV) remains an important pathogen worldwide with millions of carriers at risk of end-stage liver diseases. Despite the introduction of novel direct-acting antivirals (DAAs), resistance problems, challenges with the difficult-to-treat populations and high costs limit the widespread application of these drugs. Antivirals with alternative mechanism(s) of action, such as by restricting viral entry or cell-to-cell spread, could help expand the scope of antiviral strategies for the management of hepatitis C. Transfusion-associated HCV infection remains another issue in endemic and resource-limited areas around the world. This chapter describes some of the latest developments in antiviral strategies to preclude HCV entry, such as through monoclonal antibodies and small molecules, as well as measures to enhance the safety of therapeutic plasma products in blood transfusion.

AB - Without a preventive vaccine, hepatitis C virus (HCV) remains an important pathogen worldwide with millions of carriers at risk of end-stage liver diseases. Despite the introduction of novel direct-acting antivirals (DAAs), resistance problems, challenges with the difficult-to-treat populations and high costs limit the widespread application of these drugs. Antivirals with alternative mechanism(s) of action, such as by restricting viral entry or cell-to-cell spread, could help expand the scope of antiviral strategies for the management of hepatitis C. Transfusion-associated HCV infection remains another issue in endemic and resource-limited areas around the world. This chapter describes some of the latest developments in antiviral strategies to preclude HCV entry, such as through monoclonal antibodies and small molecules, as well as measures to enhance the safety of therapeutic plasma products in blood transfusion.

KW - hepatitis C virus

KW - viral entry

KW - antivirals

KW - entry inhibitors

KW - monoclonal antibodies

KW - small molecules

KW - therapeutic plasma products

U2 - 10.5772/65470

DO - 10.5772/65470

M3 - Chapter

SN - 978-953-51-2993-6

BT - Advances in Treatment of Hepatitis C and B

PB - InTech

ER -

Access to Document

10.5772/65470